ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Seattle Genetics will pay Unum Therapeutics $25 million to develop antibody-coupled T-cell receptor (ACTR) therapies for cancer. Unum combines engineered T cells with antibodies that can help them home in on cancer cells. Under the pact, which also calls for Seattle Genetics to make a $5 million equity investment in Unum, the partners will develop two ACTRs that use antibodies from Seattle Genetics.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X